Levosimendan mitigates coagulopathy and organ dysfunction in rats with endotoxemia.

Background: In patients with severe sepsis, pro-inflammatory cytokines and subsequent activation of tissue factors trigger a cascade of events that lead to coagulation dysfunction and multiple organ failure. It has been shown that levosimendan has protective effects against tissue injury caused by endotoxin. The purpose of this study was to evaluate the effects of levosimendan on consumptive coagulopathy and organ dysfunction in an endotoxemic animal model induced by lipopolysaccharide (LPS).

Methods: Forty-six male adult Wistar rats were randomly divided into four groups: 1) control group (n = 10), an intravenous infusion of 5% dextrose 1.2 mL/kg for 20 min and 0.03 mL/kg/min for 4 h; 2) the levosimendan-treated control group (n = 12), an intravenous levosimendan infusion (24 μg/kg for 20 min plus 0.6 μg/kg/min for 4 h); 3) the LPS group (n = 12), an intravenous LPS (4 mg/kg) infusion followed by dextrose administration; and 4) the levosimendan-treated LPS group (n = 12), an intravenous LPS infusion followed by levosimendan treatment. Various parameters of hemodynamics, biochemistry, hemostasis and inflammatory response were examined during the experimental period.

Results: The administration of levosimendan significantly attenuated (i) consumptive coagulopathy displayed by thromboelastography, (ii) the decreases of platelet count and plasma fibrinogen level, (iii) injury in the lung, liver and kidney, and (iv) the rise in plasma interleukin-6 in rats treated with LPS.

Conclusion: The treatment of LPS rats with levosimendan was found to reduce organ injury and coagulopathy. These protective effects may be attributed to the anti-inflammatory effects of this drug.